Home | News | Directories | Calendar | Maps | Contact Us | Webmail
Perelman School of Medicine at the University of Pennsylvania Advanced Search

Amit Maity, MD, PhD

Amit Maity, MD, PhD

faculty photo
Professor of Radiation Oncology at the Hospital of the University of Pennsylvania
Department: Radiation Oncology

Contact information
TRC 2West
3400 Civic Center Blvd.
Philadelphia, PA 19104
Office: 2156623759
Fax: 2153495445
BA (Mathematics)
Boston University, 1985.
MD (Medicine)
Boston University, 1985.
PhD (Pathology)
University of Pennsylvania, 1995.
Permanent link
Perelman School of Medicine > Faculty > Search

Description of Research Expertise

My laboratory based research focuses on developing strategies of improving the radiation response, using agents that modify the tumor microenvironment and alter cellular signaling. In particular we have focused on the PI3K/mTOR pathway, which is upregulated in many human cancers. Our research suggest that inhibition of this pathway can increase the intrinsic sensitivity of tumor cells to radiation and also decrease tumor oxygenation.
My clinical research focuses on using hypofractionated radiation to potentiate the action of immune checkpoint inhibitors in patient with metastatic solid tumors including melanoma, non small-lung cancer, and breast cancer.

Selected Publications

Gandhi SJ, Minn A, Vonderheide RH, Wherry EJ, Hahn SM, Maity A: Awakening the immune system with radiation: Optimal dose and fractionation. Cancer letters Mar 2015.

Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, Herati RS, Mansfield KD, Patsch D, Amaravadi RK, Schuchter LM, Ishwaran H, Mick R, Pryma DA, Xu X, Feldman MD, Gangadhar TC, Hahn SM, Wherry EJ, Vonderheide RH, Minn AJ: Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature Mar 2015.

Welsh JW, Seyedin SN, Cortez MA, Maity A, Hahn SM: Galectin-1 and immune suppression during radiotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research 20(24): 6230-2, Dec 2014.

Alonso-Basanta M, Fang P, Maity A, Hahn SM, Lustig RA, Dorsey JF: A Phase I Study of Nelfinavir Concurrent with Temozolomide and Radiotherapy in Patients with Glioblastoma Multiforme. Journal of Neurooncology 116(2): 365-72, Jan 2014.

Thompson RF, Maity A: Radiotherapy and the tumor microenvironment: mutual influence and clinical implications. Advances in Experimental Medicine and Biology 772: 147-65, 2014.

George J. Cerniglia, Souvik Dey, Shannon M. Gallagher-Colombo, Natalie Daurio, Stephen Tuttle, Theresa M. Busch, Alexander Lin, Tatiana V. Esipova, Sergei A. Vinogradov, Constantinos Koumenis, Amit Maity: The PI3K/mTOR pathway regulates oxygen metabolism via pyruvate dehydrogenase (PDH)-E1α phosphorylation. International journal of radiation oncology, biology, physics 2014 Notes: poster presentation at 56th meeting of American Society for Therapeutic Radiology and Oncology

Damek-Poprawa M, Both S, Wright A C, Maity A, Akintoye SQ: Onset of mandible and tibia osteoradionecrosis - a comparative pilot study in the rat. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology 115(2): 201-11, Feb 2013.

George J. Cerniglia, Natalie Daurio, Shannon M. Gallagher-Colombo, Theresa M. Busch, Stephen W. Tuttle, Cameron J. Koch, Alexander Lin, Constantinos Koumenis, Amit Maity: Targeting the PI3K/mTOR pathway decreases oxygen consumption and reduces tumor hypoxia International journal of radiation oncology, biology, physics 2013 Notes: accepted for Poster Discussion Session presentation at 55th meeting of American Society for Therapeutic Radiology and Oncology

Cerniglia GJ, Daurio N, Gallagher-Colombo SM, Busch TM, Tuttle SW, Koch CJ, Lin A, Koumenis C, Maity A: Agents that target the PI3K/mTOR pathway decrease oxygen consumption and reduce tumor hypoxia Proceedings of the american association for cancer research annual meeting 2013 Notes: poster presentation at 104th annual meeting, American Association for Cancer Research.

Rengan R, Mick R, Pryma D, Rosen MA, Lin L, Maity A, Evans TL, Stevenson JP, Langer CJ, Kucharczuk J, Friedberg J, Prendergast S, Sharkoski T, Hahn SM : A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer: a report of toxicities and clinical response. Journal of Thoracic Oncology 7(4): 709-15, Apr 2012

back to top
Last updated: 04/20/2015
The Trustees of the University of Pennsylvania